33. A method of treating cancer comprising administering a compound claimed in claim 1 to a host in need thereof and subsequently administering a prodrug to be activated by the enzyme portion of the compound of claim 1.--

REMARKS

Claims 1-33 are pending in this application. This preliminary amendment is being filed to put this application in compliance with the Sequence Rules and to more particularly claim applicants invention. Applicants have added claims 27-33 and amended claims 1, 5-7, and 9-13 to more accurately define the invention. Support for these amendments can be found throughout the specification as originally filed, and particularly at page 2, lines 24-29, page 4, lines 1-13, page 6, first paragraph, page 7, first paragraph and lines 18-24, Example 7 and Table 4. Accordingly, no new matter is entered.

Applicants rely on the Sequence Listing and the Computer Readable copy of the Sequence Listing submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e) submitted on December 13, 1993 in Parent Application Serial No. 08/129, 379, filed September 30, 1993. The attached Sequence Listing is a copy of the Sequence Listing filed on December 13, 1993 in Parent Application Serial No. 08/129, 379, filed September 30, 1993. The submission filed in accordance with 37 C.F.R. § 1.821(g) does not constitute new matter.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
8 DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

١. Restriction Requirement

The Examiner has required restriction under 35 U.S.C. § 121 between:

Group I: claims 1-13 and 23-26, drawn to polypeptide compounds, classified in claim 530, subclass 350 or 395; and

Group II: claims 14-22, drawn to nucleic acids, vectors, host cells and methods of recombinantly producing a protein, classified in class 536, subclass 23.5, class 435, subclass 69.1, 252.3 and 320.1.

Applicants provisionally elect to prosecute Group I, claims 1-13 and 23-26 drawn to polypeptide compounds.

Applicants await formal examination of the elected claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: October 20, 1999

Rachel H. Townsend

Reg. No. 41,443

LAW OFFICES FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P. 1300 I STREET, N. W. WASHINGTON, D. C. 20005 202-408-4000